Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | See Remarks | June 15, 2017 | June 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 15, 2017 · Filed June 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.43 · Expires 2027-06-15 | Direct | 85,000 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 85,000 · Balance 85,000 F1: This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 19, 2017 20:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Options (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0000899243-17-016671 · doc4.xml · derivative · entry 1 Subramanian Kala · CIK 0001682026 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Shares · 85,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.